(UroToday.com) In an oral presentation in the New Trials Update session at the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Marc-Oliver Grimm discussed the results of the NIMBUS trial, Treatment of High-Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of Intravesical BCG Instillations Versus Reduced Number of Intravesical Instillations with Standard Dose of BCG (NIMBUS), a European Association of Urology Research Foundation Randomised Phase III Clinical Trial of Bacillus Calmette Guerin (BCG) treatment approaches in non-muscle invasive bladder cancer.